

Immediate Report

NON-BINDING TRANSLATION

The following condensed consolidated financial statements is a free translation of the Company's consolidated financial statements in Hebrew published on the TASE on December 25, 2022. In the event of inconsistency between this version and the Hebrew one, the Hebrew language version shall prevail.

BioLight Life Sciences Ltd.

("The Company")

25th December 2022

DiagnosTear, A subsidiary company of BioLight has received positive interim results in a clinical trial in India based on its TeaRx™ technology

BioLight is proud to announce that on the 25th of December 2022, its subsidiary company DiagnosTear ("DiagnosTear") has informed her that it has received interim results in its clinical trial conducted in India to test the TeaRx Technology, its product (the "**Product**") to diagnose Dry Eye Syndrome ("**DES**"), by examining the composition of the tear fluid ("**the clinical trial**").

As reported by DiagnosTear, the interim results indicate the high performance of the product to diagnose DES in a variety of degrees of severity of the disease demonstrating a sensitivity of 79% and a specificity of 73%.

A preliminary correlation was also found between the numerical results obtained by using the product (DES Score) and the level of severity of the DES disease.

The interim results are based on testing 203 subjects who were defined as sufferers from DES and 35 subjects who were defined as healthy controls at their first visit. As communicated to the company by DiagnosTear, although these are only interim results, these results are based on the widest and most diverse cohort of subjects that DiagnosTear has performed to date.

Following the receipt of the interim results of the clinical trial, the Company and Elcam Medical Ltd. are investing the investment amount according to the last milestone as defined in the DiagnosTear investment agreement.

Forward-Looking Information Statement -The information and details contained in this report regarding the clinical trial and/or regarding the product, forecasts, deadlines, market



assessments and/or plans of the company and/or DiagnosTear, including in connection with the continuation of the clinical trial and/or its completion and/or receipt of final results (if at all), are "forward-looking information" as defined in the Securities Law, 1968 based on high certainty, among other things, on third parties and many variables over which the company and/or DiagnosTear do not necessarily have control, and therefore it is possible that the aforementioned information and estimates will not be realized in practice and/or will not be realized in full and/or will be realized in a way that is fundamentally different from what was estimated or observed from the beginning. Among the factors that may cause this can be noted, among others, failure in the continuation of the research and development processes of the product, including failure in the continuation of the trial (if it continues) / or in additional clinical trials, worsening and / or changes in regulatory requirements and the realization of any of the risk factors as detailed in section 4.27 in chapter A of the company's annual report, which may have a significant effect, together and separately, on the company's assessments and diagnostics as mentioned.

About DiagnosTear

DiagnosTear's TeaRx™ technology is a diagnostic platform intended for diagnosis of disease in the frontal areas of the eye through examination of several substances in the composition of teardrops. The first indication is for identification, personal matching and monitoring of Dry Eye Syndrome (DES).

About BioLight

BioLight Life Sciences Ltd. is a publicly traded Israeli company investing in companies and managing projects in Ophthalmology. BioLight's portfolio companies engage in medical devices, medication, diagnostics and digital medicine and all exemplifying the enormous potential of innovation in the ophthalmological technologies mainly in Israel. For detailed information on BioLight and its portfolio companies. please visit www.bio-light.co.il

